Monopar Therapeutics — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2021-02-11

Reporting Person: Tactic Pharma LLC (N/A)
Reporting Person: Mazar Andrew Paul (N/A)
Reporting Person: Robinson Chandler (N/A)
Reporting Person: O'Halloran Thomas V. (N/A)
Reporting Person: Brown Michael J (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-11	Common stock	S	42467	$13.30	Disposed	249200	Direct
2021-02-11	Common stock	S	24224	$14.09	Disposed	224976	Direct
2021-02-11	Common stock	S	29996	$15.12	Disposed	194980	Direct
2021-02-11	Common stock	S	16384	$16.44	Disposed	178596	Direct
2021-02-11	Common stock	S	11929	$16.90	Disposed	166667	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	4111272.88	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020.

F2: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The
reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive.

F8: Tactic shares voting and investment power over 4,111,272.88 of the shares of common stock held by TacticGem LLC.